RecruitingNot ApplicableNCT06542796

Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma


Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

100 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Through a retrospective study of patients who underwent comprehensive treatment for hepatocellular carcinoma at the Second Affiliated Hospital of Zhejiang University, we explored the risk factors related to the sensitivity of comprehensive treatment. We used the PD-L1 expression level of patients before comprehensive treatment,characteristic morphology of tertiary lymphoid structures, as well as other parameters, are used to construct a liver cancer comprehensive treatment efficacy evaluation model. Using this liver cancer comprehensive treatment efficacy evaluation model, we conducted a randomized controlled trial on whether to receive comprehensive treatment for liver cancer patients to verify the accuracy and practical value of the model.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how well different treatments work for people with advanced liver cancer (hepatocellular carcinoma) and aims to better classify treatment outcomes. **You may be eligible if...** - You have been diagnosed with advanced liver cancer **You may NOT be eligible if...** - You have serious diabetes, heart failure, or liver/kidney failure - You have a history of schizophrenia - You have had other cancers or liver tumors found after surgery - You have previously received anti-cancer drugs for other conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREImmunotherapy combined with targeted therapy

Immunotherapy combined with targeted therapy

OTHERStandard treatment plan

Standard treatment plan


Locations(1)

2ndAffiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06542796


Related Trials